Global Primary Biliary Cirrhosis Drug Market Professional Survey Report 2019

Table of Contents

Executive Summary

1 Industry Overview of Primary Biliary Cirrhosis Drug

• 1.1 Definition of Primary Biliary Cirrhosis Drug
• 1.2 Primary Biliary Cirrhosis Drug Segment by Type
  • 1.2.1 Global Primary Biliary Cirrhosis Drug Production Growth Rate Comparison by Types (2014-2025)
  • 1.2.2 Budesonide
  • 1.2.3 FFP-104
  • 1.2.4 GSK-2330672
  • 1.2.5 MBX-8025
  • 1.2.6 NGM-282
  • 1.2.7 Others
• 1.3 Primary Biliary Cirrhosis Drug Segment by Applications
  • 1.3.1 Global Primary Biliary Cirrhosis Drug Consumption Comparison by Applications (2014-2025)
  • 1.3.2 Clinic
  • 1.3.3 Hospital
  • 1.3.4 Others
• 1.4 Global Primary Biliary Cirrhosis Drug Overall Market
  • 1.4.1 Global Primary Biliary Cirrhosis Drug Revenue (2014-2025)
  • 1.4.2 Global Primary Biliary Cirrhosis Drug Production (2014-2025)
  • 1.4.3 North America Primary Biliary Cirrhosis Drug Status and Prospect (2014-2025)
  • 1.4.4 Europe Primary Biliary Cirrhosis Drug Status and Prospect (2014-2025)
  • 1.4.5 China Primary Biliary Cirrhosis Drug Status and Prospect (2014-2025)
  • 1.4.6 Japan Primary Biliary Cirrhosis Drug Status and Prospect (2014-2025)
  • 1.4.7 Southeast Asia Primary Biliary Cirrhosis Drug Status and Prospect (2014-2025)
  • 1.4.8 India Primary Biliary Cirrhosis Drug Status and Prospect (2014-2025)

2 Manufacturing Cost Structure Analysis

• 2.1 Raw Material and Suppliers
• 2.2 Manufacturing Cost Structure Analysis of Primary Biliary Cirrhosis Drug
• 2.3 Manufacturing Process Analysis of Primary Biliary Cirrhosis Drug
• 2.4 Industry Chain Structure of Primary Biliary Cirrhosis Drug

3 Development and Manufacturing Plants Analysis of Primary Biliary Cirrhosis Drug

• 3.1 Capacity and Commercial Production Date
• 3.2 Global Primary Biliary Cirrhosis Drug Manufacturing Plants Distribution
• 3.3 Major Manufacturers Technology Source and Market Position of Primary Biliary Cirrhosis Drug
• 3.4 Recent Development and Expansion Plans

4 Key Figures of Major Manufacturers

• 4.1 Primary Biliary Cirrhosis Drug Production and Capacity Analysis
• 4.2 Primary Biliary Cirrhosis Drug Revenue Analysis
• 4.3 Primary Biliary Cirrhosis Drug Price Analysis
• 4.4 Market Concentration Degree

5 Primary Biliary Cirrhosis Drug Regional Market Analysis

• 5.1 Primary Biliary Cirrhosis Drug Production by Regions
  • 5.1.1 Global Primary Biliary Cirrhosis Drug Production by Regions
  • 5.1.2 Global Primary Biliary Cirrhosis Drug Revenue by Regions
• 5.2 Primary Biliary Cirrhosis Drug Consumption by Regions
• 5.3 North America Primary Biliary Cirrhosis Drug Market Analysis
  • 5.3.1 North America Primary Biliary Cirrhosis Drug Production
  • 5.3.2 North America Primary Biliary Cirrhosis Drug Revenue
  • 5.3.3 Key Manufacturers in North America
  • 5.3.4 North America Primary Biliary Cirrhosis Drug Import and Export
• 5.4 Europe Primary Biliary Cirrhosis Drug Market Analysis
  • 5.4.1 Europe Primary Biliary Cirrhosis Drug Production
  • 5.4.2 Europe Primary Biliary Cirrhosis Drug Revenue
  • 5.4.3 Key Manufacturers in Europe
  • 5.4.4 Europe Primary Biliary Cirrhosis Drug Import and Export
• 5.5 China Primary Biliary Cirrhosis Drug Market Analysis
  • 5.5.1 China Primary Biliary Cirrhosis Drug Production
  • 5.5.2 China Primary Biliary Cirrhosis Drug Revenue
  • 5.5.3 Key Manufacturers in China
  • 5.5.4 China Primary Biliary Cirrhosis Drug Import and Export
• 5.6 Japan Primary Biliary Cirrhosis Drug Market Analysis
  • 5.6.1 Japan Primary Biliary Cirrhosis Drug Production
  • 5.6.2 Japan Primary Biliary Cirrhosis Drug Revenue
  • 5.6.3 Key Manufacturers in Japan
  • 5.6.4 Japan Primary Biliary Cirrhosis Drug Import and Export
• 5.7 Southeast Asia Primary Biliary Cirrhosis Drug Market Analysis
  • 5.7.1 Southeast Asia Primary Biliary Cirrhosis Drug Production
  • 5.7.2 Southeast Asia Primary Biliary Cirrhosis Drug Revenue
  • 5.7.3 Key Manufacturers in Southeast Asia
  • 5.7.4 Southeast Asia Primary Biliary Cirrhosis Drug Import and Export
• 5.8 India Primary Biliary Cirrhosis Drug Market Analysis
  • 5.8.1 India Primary Biliary Cirrhosis Drug Production
  • 5.8.2 India Primary Biliary Cirrhosis Drug Revenue
  • 5.8.3 Key Manufacturers in India
  • 5.8.4 India Primary Biliary Cirrhosis Drug Import and Export

6 Primary Biliary Cirrhosis Drug Segment Market Analysis (by Type)

• 6.1 Global Primary Biliary Cirrhosis Drug Production by Type
• 6.2 Global Primary Biliary Cirrhosis Drug Revenue by Type
• 6.3 Primary Biliary Cirrhosis Drug Price by Type

7 Primary Biliary Cirrhosis Drug Segment Market Analysis (by Application)

• 7.1 Global Primary Biliary Cirrhosis Drug Consumption by Application
• 7.2 Global Primary Biliary Cirrhosis Drug Consumption Market Share by Application (2014-2019)

8 Primary Biliary Cirrhosis Drug Major Manufacturers Analysis

• 8.1 AlbireoPharma
  • 8.1.1 AlbireoPharma Primary Biliary Cirrhosis Drug Production Sites and Area Served
  • 8.1.2 AlbireoPharma Product Introduction, Application and Specification
  • 8.1.3 AlbireoPharma Primary Biliary Cirrhosis Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.1.4 Main Business and Markets Served
• 8.2 CymaBay Therapeutics, Inc.
  • 8.2.1 CymaBay Therapeutics, Inc. Primary Biliary Cirrhosis Drug Production Sites and Area Served
  • 8.2.2 CymaBay Therapeutics, Inc. Product Introduction, Application and Specification
  • 8.2.3 CymaBay Therapeutics, Inc. Primary Biliary Cirrhosis Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.2.4 Main Business and Markets Served
• 8.3 Dr. Falk Pharma GmbH
  • 8.3.1 Dr. Falk Pharma GmbH Primary Biliary Cirrhosis Drug Production Sites and Area Served
  • 8.3.2 Dr. Falk Pharma GmbH Product Introduction, Application and Specification
  • 8.3.3 Dr. Falk Pharma GmbH Primary Biliary Cirrhosis Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.3.4 Main Business and Markets Served
• 8.4 Enanta Pharmaceuticals, Inc.
  • 8.4.1 Enanta Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Production Sites and Area Served
  • 8.4.2 Enanta Pharmaceuticals, Inc. Product Introduction, Application and Specification
  • 8.4.3 Enanta Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.4.4 Main Business and Markets Served
• 8.5 GlaxoSmithKline Plc
  • 8.5.1 GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug Production Sites and Area Served
  • 8.5.2 GlaxoSmithKline Plc Product Introduction, Application and Specification
  • 8.5.3 GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.5.4 Main Business and Markets Served
• 8.6 Intercept Pharmaceuticals, Inc.
  • 8.6.1 Intercept Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Production Sites and Area Served
  • 8.6.2 Intercept Pharmaceuticals, Inc. Product Introduction, Application and Specification
  • 8.6.3 Intercept Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.6.4 Main Business and Markets Served
• 8.7 Johnson & Johnson
  • 8.7.1 Johnson & Johnson Primary Biliary Cirrhosis Drug Production Sites and Area Served
  • 8.7.2 Johnson & Johnson Product Introduction, Application and Specification
  • 8.7.3 Johnson & Johnson Primary Biliary Cirrhosis Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.7.4 Main Business and Markets Served
• 8.8 MediGene AG
  • 8.8.1 MediGene AG Primary Biliary Cirrhosis Drug Production Sites and Area Served
  • 8.8.2 MediGene AG Product Introduction, Application and Specification
  • 8.8.3 MediGene AG Primary Biliary Cirrhosis Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.8.4 Main Business and Markets Served
• 8.9 NGM Biopharmaceuticals, Inc.
  • 8.9.1 NGM Biopharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Production Sites and Area Served
  • 8.9.2 NGM Biopharmaceuticals, Inc. Product Introduction, Application and Specification
  • 8.9.3 NGM Biopharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.9.4 Main Business and Markets Served
• 8.10 Virobay Inc.
  • 8.10.1 Virobay Inc. Primary Biliary Cirrhosis Drug Production Sites and Area Served
  • 8.10.2 Virobay Inc. Product Introduction, Application and Specification
  • 8.10.3 Virobay Inc. Primary Biliary Cirrhosis Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.10.4 Main Business and Markets Served

9 Development Trend of Analysis of Primary Biliary Cirrhosis Drug Market

• 9.1 Global Primary Biliary Cirrhosis Drug Market Trend Analysis
  • 9.1.1 Global Primary Biliary Cirrhosis Drug Market Size (Volume and Value) Forecast 2019-2025
• 9.2 Primary Biliary Cirrhosis Drug Regional Market Trend
  • 9.2.1 North America Primary Biliary Cirrhosis Drug Forecast 2019-2025
  • 9.2.2 Europe Primary Biliary Cirrhosis Drug Forecast 2019-2025
  • 9.2.3 China Primary Biliary Cirrhosis Drug Forecast 2019-2025
  • 9.2.4 Japan Primary Biliary Cirrhosis Drug Forecast 2019-2025
  • 9.2.5 Southeast Asia Primary Biliary Cirrhosis Drug Forecast 2019-2025
  • 9.2.6 India Primary Biliary Cirrhosis Drug Forecast 2019-2025
• 9.3 Primary Biliary Cirrhosis Drug Market Trend (Product Type)
• 9.4 Primary Biliary Cirrhosis Drug Market Trend (Application)
• 10.1 Marketing Channel
  • 10.1.1 Direct Marketing
  • 10.1.2 Indirect Marketing
• 10.3 Primary Biliary Cirrhosis Drug Customers

11 Market Dynamics

• 11.1 Market Trends
• 11.2 Opportunities
• 11.3 Market Drivers
• 11.4 Challenges
• 11.5 Influence Factors

12 Conclusion

13 Appendix

• 13.1 Methodology/Research Approach
  • 13.1.1 Research Programs/Design
  • 13.1.2 Market Size Estimation
  • 13.1.3 Market Breakdown and Data Triangulation
• 13.2 Data Source
  • 13.2.1 Secondary Sources
  • 13.2.2 Primary Sources
• 13.3 Author List